Immutep Historical Income Statement

IMMP Stock

USD 2.03 0.04 2.01%

Historical analysis of Immutep income statement accounts such as Selling General Administrative of 9.3 M or Other Operating Expenses of 96.5 M can show how well Immutep Ltd ADR performed in making a profits. Evaluating Immutep income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Immutep's future profits or losses.

Cash Flow Balance Sheet Income Statement

Credit Downgrade

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining Immutep Ltd ADR latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Immutep Ltd ADR is a good buy for the upcoming year.

Net Income Gross Profit

Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Immutep Ltd ADR. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.

About Immutep Income Statement Analysis

Immutep Ltd ADR Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Immutep shareholders. The income statement also shows Immutep investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

Immutep Income Statement Chart

At this time, Immutep's Selling General Administrative is relatively stable compared to the past year. As of 11/30/2024, Other Operating Expenses is likely to grow to about 96.5 M, though Operating Income is likely to grow to (83.7 M).

Interest Expense Selling General Administrative Other Operating Expenses Research Development Total Operating Expenses Interest Income

Interest Expense

The cost incurred by an entity for borrowed funds, including loans, bonds, or lines of credit.

Other Operating Expenses

Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Immutep Ltd ADR. It is also known as Immutep overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.

Total Operating Expenses

The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.

Interest Income

Income earned from the investment of cash or from lending money to others, including interest from bank accounts, bonds, or other interest-bearing investments.

Most accounts from Immutep's income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Immutep Ltd ADR current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Immutep Ltd ADR. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.

	2021	2023	2024 (projected)
Reconciled Depreciation	3.0M	3.4M	2.3M
Net Interest Income	192.0K	1.1M	1.1M

Reconciled Depreciation Net Interest Income

Immutep income statement Correlations

	Depreciation And Amortization	Interest Expense	Selling General Administrative	Other Operating Expenses	Operating Income	Ebit	Research Development	Ebitda	Total Operating Expenses	Income Before Tax	Total Other Income Expense Net	Net Income	Income Tax Expense	Total Revenue	Gross Profit	Cost Of Revenue	Net Income From Continuing Ops	Tax Provision	Interest Income	Net Interest Income	Reconciled Depreciation	Selling And Marketing Expenses
Depreciation And Amortization		-0.03	0.29	0.35	-0.38	-0.47	0.4	-0.44	0.47	-0.51	0.16	-0.5	-0.3	0.17	-0.33	0.33	-0.51	-0.06	-0.9	0.16	0.53	-0.06
Interest Expense	-0.03		-0.08	-0.17	0.16	0.17	-0.2	0.17	-0.18	-0.11	-0.11	-0.12	0.06	-0.08	0.18	-0.18	0.17	0.03	0.38	-0.1	-0.19	0.1
Selling General Administrative	0.29	-0.08		0.4	-0.43	-0.72	-0.11	-0.72	0.66	-0.73	-0.05	-0.72	-0.39	-0.32	-0.09	0.04	-0.71	-0.77	-0.25	0.0	-0.09	0.01
Other Operating Expenses	0.35	-0.17	0.4		-0.99	-0.86	0.8	-0.86	0.91	-0.76	0.87	-0.77	0.05	0.02	-0.81	0.8	-0.69	-0.04	-0.43	0.83	0.62	-0.82
Operating Income	-0.38	0.16	-0.43	-0.99		0.89	-0.79	0.89	-0.93	0.8	-0.84	0.81	0.0	0.03	0.78	-0.76	0.74	0.07	0.45	-0.83	-0.65	0.77
Ebit	-0.47	0.17	-0.72	-0.86	0.89		-0.58	1.0	-0.99	0.94	-0.5	0.94	0.16	0.18	0.49	-0.46	0.92	0.32	0.47	-0.6	-0.54	0.45
Research Development	0.4	-0.2	-0.11	0.8	-0.79	-0.58		-0.57	0.66	-0.47	0.82	-0.48	0.24	0.21	-0.72	0.74	-0.46	0.45	-0.47	0.8	0.83	-0.74
Ebitda	-0.44	0.17	-0.72	-0.86	0.89	1.0	-0.57		-0.98	0.93	-0.5	0.93	0.15	0.19	0.48	-0.45	0.91	0.33	0.43	-0.6	-0.53	0.45
Total Operating Expenses	0.47	-0.18	0.66	0.91	-0.93	-0.99	0.66	-0.98		-0.91	0.58	-0.91	-0.08	-0.09	-0.58	0.56	-0.88	-0.24	-0.48	0.66	0.56	-0.55
Income Before Tax	-0.51	-0.11	-0.73	-0.76	0.8	0.94	-0.47	0.93	-0.91		-0.4	1.0	0.14	0.22	0.36	-0.33	0.9	0.34	0.39	-0.48	-0.46	0.37
Total Other Income Expense Net	0.16	-0.11	-0.05	0.87	-0.84	-0.5	0.82	-0.5	0.58	-0.4		-0.41	0.19	0.18	-0.89	0.9	-0.31	0.27	-0.29	0.86	0.59	-0.94
Net Income	-0.5	-0.12	-0.72	-0.77	0.81	0.94	-0.48	0.93	-0.91	1.0	-0.41		0.1	0.2	0.36	-0.33	0.9	0.33	0.38	-0.49	-0.47	0.37
Income Tax Expense	-0.3	0.06	-0.39	0.05	0.0	0.16	0.24	0.15	-0.08	0.14	0.19	0.1		0.43	0.11	-0.03	0.14	0.43	0.31	0.11	0.25	-0.17
Total Revenue	0.17	-0.08	-0.32	0.02	0.03	0.18	0.21	0.19	-0.09	0.22	0.18	0.2	0.43		-0.13	0.26	0.33	0.23	-0.17	0.07	0.12	-0.1
Gross Profit	-0.33	0.18	-0.09	-0.81	0.78	0.49	-0.72	0.48	-0.58	0.36	-0.89	0.36	0.11	-0.13		-0.99	0.3	-0.21	0.47	-0.73	-0.49	0.83
Cost Of Revenue	0.33	-0.18	0.04	0.8	-0.76	-0.46	0.74	-0.45	0.56	-0.33	0.9	-0.33	-0.03	0.26	-0.99		-0.25	0.24	-0.47	0.73	0.47	-0.85
Net Income From Continuing Ops	-0.51	0.17	-0.71	-0.69	0.74	0.92	-0.46	0.91	-0.88	0.9	-0.31	0.9	0.14	0.33	0.3	-0.25		0.32	0.49	-0.4	-0.54	0.29
Tax Provision	-0.06	0.03	-0.77	-0.04	0.07	0.32	0.45	0.33	-0.24	0.34	0.27	0.33	0.43	0.23	-0.21	0.24	0.32		0.06	0.28	0.39	-0.2
Interest Income	-0.9	0.38	-0.25	-0.43	0.45	0.47	-0.47	0.43	-0.48	0.39	-0.29	0.38	0.31	-0.17	0.47	-0.47	0.49	0.06		-0.25	-0.5	0.25
Net Interest Income	0.16	-0.1	0.0	0.83	-0.83	-0.6	0.8	-0.6	0.66	-0.48	0.86	-0.49	0.11	0.07	-0.73	0.73	-0.4	0.28	-0.25		0.66	-0.79
Reconciled Depreciation	0.53	-0.19	-0.09	0.62	-0.65	-0.54	0.83	-0.53	0.56	-0.46	0.59	-0.47	0.25	0.12	-0.49	0.47	-0.54	0.39	-0.5	0.66		-0.39
Selling And Marketing Expenses	-0.06	0.1	0.01	-0.82	0.77	0.45	-0.74	0.45	-0.55	0.37	-0.94	0.37	-0.17	-0.1	0.83	-0.85	0.29	-0.2	0.25	-0.79	-0.39

Click cells to compare fundamentals

Immutep Account Relationship Matchups

Immutep income statement Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Depreciation And Amortization	2.1M	2.1M	2.1M	2.1M	2.0M	1.3M
Interest Expense	10.5K	9.8K	92.4K	20.4K	30.6K	29.1K
Selling General Administrative	6.3M	6.3M	7.2M	8.7M	8.9M	9.3M
Other Operating Expenses	22.6M	19.7M	34.0M	44.9M	91.9M	96.5M
Operating Income	(16.0M)	(19.6M)	(33.9M)	(44.9M)	(88.1M)	(83.7M)
Ebit	(16.0M)	(19.8M)	(33.9M)	(41.6M)	(46.6M)	(44.2M)
Research Development	20.4M	17.2M	31.3M	28.8M	41.5M	43.6M
Ebitda	(13.9M)	(17.8M)	(31.9M)	(39.6M)	(44.5M)	(42.3M)
Total Operating Expenses	22.6M	19.7M	34.0M	42.9M	50.4M	52.9M
Income Before Tax	(13.5M)	(29.9M)	(32.2M)	(39.9M)	(42.7M)	(40.6M)
Total Other Income Expense Net	2.6M	1.8M	1.6M	5.0M	45.4M	47.7M
Net Income	(13.5M)	(29.9M)	(32.2M)	(39.9M)	(42.7M)	(40.6M)
Income Tax Expense	37.0	33.0	34.0	2.0	1.8	1.71
Total Revenue	7.5M	4.0M	170.4K	3.5M	3.8M	2.9M
Gross Profit	(15.0M)	1.9M	(1.9M)	1.4M	(37.7M)	(35.8M)
Cost Of Revenue	22.5M	2.1M	2.1M	2.1M	41.5M	43.6M
Net Income From Continuing Ops	(13.5M)	(29.9M)	(46.8M)	(39.9M)	(35.9M)	(37.7M)
Net Income Applicable To Common Shares	(13.5M)	(29.9M)	(32.2M)	(39.9M)	(35.9M)	(37.7M)
Interest Income	199.5K	105.3K	326.4K	939.0K	845.1K	802.8K
Net Interest Income	189.1K	95.5K	192.0K	918.6K	1.1M	1.1M
Reconciled Depreciation	1.9M	2.1M	2.2M	3.0M	3.4M	2.3M

Pair Trading with Immutep

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Immutep position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Immutep will appreciate offsetting losses from the drop in the long position's value.

Moving together with Immutep Stock

0.73

ELAN

Elanco Animal Health

Pair Corr

Moving against Immutep Stock

0.92	EWTX	Edgewise Therapeutics	Pair Corr
0.88	BHC	Bausch Health Companies	Pair Corr
0.84	GILD	Gilead Sciences	Pair Corr
0.76	GANX	Gain Therapeutics	Pair Corr
0.75	BMY	Bristol Myers Squibb Sell-off Trend	Pair Corr

The ability to find closely correlated positions to Immutep could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Immutep when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Immutep - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Immutep Ltd ADR to buy it.

The correlation of Immutep is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Immutep moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Immutep Ltd ADR moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Immutep can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

Additional Tools for Immutep Stock Analysis

When running Immutep's price analysis, check to measure Immutep's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immutep is operating at the current time. Most of Immutep's value examination focuses on studying past and present price action to predict the probability of Immutep's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immutep's price. Additionally, you may evaluate how the addition of Immutep to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Immutep Historical Income Statement

About Immutep Income Statement Analysis

Immutep Income Statement Chart

Interest Expense

Other Operating Expenses

Total Operating Expenses

Interest Income

Immutep income statement Correlations

Immutep Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Immutep income statement Accounts

Pair Trading with Immutep

Moving together with Immutep Stock

Moving against Immutep Stock

Additional Tools for Immutep Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Ebitda	+ 1.0	Ebit
Net Income	+ 1.0	Income Before Tax
Income Before Tax	+ 0.94	Ebit
Net Income	+ 0.94	Ebit
Income Before Tax	+ 0.93	Ebitda
Net Income	+ 0.93	Ebitda

Cost Of Revenue	- 0.99	Gross Profit
Total Operating Expenses	- 0.99	Ebit
Operating Income	- 0.99	Other Operating Expenses
Total Operating Expenses	- 0.98	Ebitda
Selling And Marketing Expenses	- 0.94	Total Other Income Expense Net
Total Operating Expenses	- 0.93	Operating Income